PROLACTIN AN ANTIANGIOGENIC FACTOR
催乳素是一种抗血管生成因子
基本信息
- 批准号:3247711
- 负责人:
- 金额:$ 16.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-06-11 至 1996-05-31
- 项目状态:已结题
- 来源:
- 关键词:3T3 cells B lymphocyte SDS polyacrylamide gel electrophoresis angiogenesis angiogenesis factor athymic mouse chick embryo chorioallantoic membrane epidermal growth factor fibroblast growth factor fusion gene genetic library genetically modified animals growth factor receptors growth inhibitors hormone regulation /control mechanism laboratory mouse neoplastic cell neoplastic growth polymerase chain reaction prolactin protease inhibitor recombinant proteins transfection /expression vector vascular endothelium
项目摘要
An essential component of the multistep process of tumorigenesis is the
development of a new blood supply, angiogenesis. A strategy in
inhibition of tumor formation and growth is to inhibit
neovascularization. We have shown that the 16 kd n terminal fragment
of prolactin (16K PRL) is a specific angiolytic factor in vitro. Both
rat and recombinant human 16K PRL inhibits basal and bFGF or VEGF
stimulated growth of bovine and human vascular endothelial cells. 16K
PRL also inhibits organization of capillary endothelial cells into
capillary like structures when cultured in collagen gels. Finally 16K
PRL inhibits development of the microvasculature in the chick
chorioallantoic membrane.
We will determine if 16K PRL inhibits activation of proteases in
capillary endothelial cells by BFGF. In the chick chorioallantoic
membrane we will determine if 16K PRL also inhibits the angiogenic
actions of bFGF and VEGF.
We will determine if 16K PRL inhibits tumor growth and associated
angiogenesis in two model systems. NIH 3T3 cells transformed by
transfections with a signal peptide FGF expression vector or the HCT
16 human colon carcinoma cells will be transplanted subcutaneously into
nude athymic mice. 16K PRL will be administered systemically or
intratumorally and the growth and vascularization of tumor
histologically evaluated. In another model lines of transgenic mice
will be developed in which 16K hPRL expression is directed to beta
cells of the pancreas. This will be accomplished by constructing a
chimeric gene consisting of the insulin promoter/enhancer elements (In)
upstream from the coding region for 16K hPRL. These mice will then be
crossed with transgenic mice expressing SV40 T antigen in the beta
cells of the pancreas (In-Tag). The In-Tag mice are well characterized
and develop time dependent tumors of the pancreas. Frequency, rate of
growth and vascularization of tumors will be evaluated.
The angiolytic action of 16K PRL is mediated via a novel receptor which
is not the prolactin or FGF receptors. We will attempt to clone the
receptor by two approaches. (1) Expression cloning in COS cells. A
bovine brain capillary endothelial cell (BBE) cDNA library in pcDNA1
vector will be expressed in COS cells and screened by autoradiographic
analysis of I-125 16K PRL binding. (2) Homology to GH/PRL/Interleukin
receptor family: PCR fragments obtained with primers to conserved
region of the receptor family will be used to screen cDNA libraries of
BBE or human umbilical vein endothelial cells.
肿瘤发生的多步骤过程中的一个重要组成部分是
开发一种新的血液供应,血管生成。在中国的战略
抑制肿瘤的形成和生长就是抑制
新生血管。我们已经证明了16kdn末端片段
催乳素(16K-PRL)在体外是一种特异的血管溶解因子。两者都有
大鼠和重组人16K催乳素抑制碱性成纤维细胞生长因子和血管内皮生长因子
刺激牛和人血管内皮细胞的生长。16K
催乳素还抑制毛细血管内皮细胞的组织
在胶原胶中培养时,可形成毛细血管样结构。最后是16K
催乳素抑制雏鸡微血管的发育
绒毛尿囊膜。
我们将确定16K PRL是否抑制蛋白水解酶的激活
碱性成纤维细胞生长因子诱导的毛细血管内皮细胞。在鸡绒毛膜尿囊症中
我们将确定16K PRL是否也抑制血管生成
碱性成纤维细胞生长因子和血管内皮生长因子的作用。
我们将确定16K催乳素是否抑制肿瘤生长并与
两个模型系统中的血管生成。转化的NIH3T3细胞
信号肽成纤维细胞生长因子表达载体或HCT的转染法
16个人结肠癌细胞将被移植到皮下
裸体裸鼠。16K PRL将系统管理或
肿瘤内与肿瘤生长和血运的关系
组织学评估。在另一种转基因小鼠模型系中
将开发其中16K hPRL表达定向到测试版
胰腺细胞。这将通过构造一个
由胰岛素启动子/增强子元件(In)组成的嵌合基因
16K hPRL编码区的上游。然后这些老鼠就会被
与表达SV40T抗原的转基因小鼠杂交
胰腺细胞(标记内)。标签内的小鼠有很好的特征
并发展成时间依赖性的胰腺肿瘤。频率、频率、频率
将对肿瘤的生长和血管形成进行评估。
16K PRL的血管溶解作用是通过一种新的受体介导的,该受体
不是催乳素或成纤维细胞生长因子受体。我们将尝试克隆
受体通过两种途径。(1)COS细胞表达克隆。一个
PcDNA1中的牛脑毛细血管内皮细胞(BBE)cDNA文库
载体将在COS细胞中表达,并通过放射自显影筛选
I-125 16K催乳素结合分析。(2)生长激素/催乳素/白介素同源
受体家族:用聚合酶链式反应扩增片段
该受体家族的区域将被用来筛选
BBE或人脐静脉内皮细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD Ira WEINER其他文献
RICHARD Ira WEINER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD Ira WEINER', 18)}}的其他基金
Antiangiogenic action 16k hPRL in retinal microvessels
16k hPRL 在视网膜微血管中的抗血管生成作用
- 批准号:
7012255 - 财政年份:2005
- 资助金额:
$ 16.22万 - 项目类别:
Antiangiogenic action 16k hPRL in retinal microvessels
16k hPRL 在视网膜微血管中的抗血管生成作用
- 批准号:
7171798 - 财政年份:2005
- 资助金额:
$ 16.22万 - 项目类别:
Antiangiogenic action 16k hPRL in retinal microvessels
16k hPRL 在视网膜微血管中的抗血管生成作用
- 批准号:
6866094 - 财政年份:2005
- 资助金额:
$ 16.22万 - 项目类别:
相似海外基金
Modulation of T-/B-lymphocyte immigration affects subsequent allograft damage (B06)
T/B 淋巴细胞迁移的调节会影响随后的同种异体移植物损伤 (B06)
- 批准号:
517500221 - 财政年份:2023
- 资助金额:
$ 16.22万 - 项目类别:
CRC/Transregios
development of therapeutic strategy for immune related adverse events by immune checkpoint inhivitor by focusing on B lymphocyte
以B淋巴细胞为重点,制定免疫检查点抑制剂免疫相关不良事件的治疗策略
- 批准号:
22K08541 - 财政年份:2022
- 资助金额:
$ 16.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Role and Regulation of Monocarboxylate Transporters 1 and 4 in Epstein-Barr Virus-mediated B Lymphocyte Tumorigenesis
单羧酸转运蛋白1和4在EB病毒介导的B淋巴细胞肿瘤发生中的作用和调节
- 批准号:
10154328 - 财政年份:2021
- 资助金额:
$ 16.22万 - 项目类别:
Dissecting Hem-1 functions in B lymphocyte Development and Primary Immunodeficiency Disease
剖析 Hem-1 在 B 淋巴细胞发育和原发性免疫缺陷病中的功能
- 批准号:
10385848 - 财政年份:2021
- 资助金额:
$ 16.22万 - 项目类别:
The Role and Regulation of Monocarboxylate Transporters 1 and 4 in Epstein-Barr Virus-mediated B Lymphocyte Tumorigenesis
单羧酸转运蛋白1和4在EB病毒介导的B淋巴细胞肿瘤发生中的作用和调节
- 批准号:
10364632 - 财政年份:2021
- 资助金额:
$ 16.22万 - 项目类别:
The role of Semaphorin 4C-PlexinB2 interaction in B-lymphocyte differentiation
Semaphorin 4C-PlexinB2 相互作用在 B 淋巴细胞分化中的作用
- 批准号:
RGPIN-2017-06735 - 财政年份:2021
- 资助金额:
$ 16.22万 - 项目类别:
Discovery Grants Program - Individual
Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease
儿童镰状细胞病 B 淋巴细胞缺乏的特征
- 批准号:
10641800 - 财政年份:2020
- 资助金额:
$ 16.22万 - 项目类别:
Functional Consequences of Ubiquitin Depletion During B Lymphocyte Differentiation
B 淋巴细胞分化过程中泛素耗竭的功能后果
- 批准号:
10055003 - 财政年份:2020
- 资助金额:
$ 16.22万 - 项目类别:
Functional Consequences of Ubiquitin Depletion During B Lymphocyte Differentiation
B 淋巴细胞分化过程中泛素耗竭的功能后果
- 批准号:
10684125 - 财政年份:2020
- 资助金额:
$ 16.22万 - 项目类别:
How does aberrant B lymphocyte produce a origin of multiple myeloma cells?
异常B淋巴细胞如何产生多发性骨髓瘤细胞的起源?
- 批准号:
20K08738 - 财政年份:2020
- 资助金额:
$ 16.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




